Back to Resources
Market Highlights
- In the European gastric and esophageal cancer market, most materials were direct mail in digital format, targeting physicians with promotions mainly circulating in Germany. Patient access in terms of price and ease of use, efficacy, and expanded approvals were publicized.
- MSD announced a price reduction for Keytruda 25 mg/mL and a new packaging format. The brand was positioned as the only approved anti–PD-1 combination therapy for both HER2+ and HER2- advanced or metastatic gastric and GEJ adenocarcinoma, with first-line use supported by KEYNOTE studies. A new indication was announced, while the “Key” campaign was displayed.
- Bristol Myers Squibb publicized Opdivo’s superior efficacy in terms of overall survival when combined with chemotherapy in HER2-negative advanced gastric cancer. The campaign also celebrated Opdivo’s 10th anniversary and noted fully reimbursed indications.
- Astellas positioned Vyloy as a new first-line therapy targeting Claudin 18.2 in combination with chemotherapy for advanced/metastatic HER2-gastric/GEJ adenocarcinoma. SPOTLIGHT showed survival improvement, while testing was emphasized. The “Focus” campaign was observed.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com